Longitudinal change in collagen degradation biomarkers in idiopathic pulmonary fibrosis: An analysis from the prospective, multicentre PROFILE study

The Lancet Respiratory Medicine

Volumn 3, Issue 6, 2015, Pages 462-472

  Jenkins, R Gisli ^a   Simpson, Juliet K ^b   Saini, Gauri ^a   Bentley, Jane H ^b   Russell, Anne Marie ^c   Braybrooke, Rebecca ^a   Molyneaux, Philip L ^d   McKeever, Tricia M ^a   Wells, Athol U ^c   Flynn, Aiden ^b   Hubbard, Richard B ^a   Leeming, Diana J ^e   Marshall, Richard P ^b   Karsdal, Morten A ^e   Lukey, Pauline T ^b   Maher, Toby M ^c,d  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b GLAXOSMITHKLINE   (United Kingdom)

^c ROYAL BROMPTON HOSPITAL   (United Kingdom)

^d NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^e NORDIC BIOSCIENCE A S   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ADAMTS1 PROTEIN; AGGRECANASE 1; BIGLYCAN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; COLLAGEN; COLLAGEN TYPE 1; COLLAGEN TYPE 3; COLLAGEN TYPE 5; COLLAGEN TYPE 6; COLLAGENASE 3; ELASTIN; EPITOPE; GELATINASE A; GELATINASE B; INTERSTITIAL COLLAGENASE; MACROPHAGE ELASTASE; MATRIX METALLOPROTEINASE; NEUTROPHIL COLLAGENASE; SCLEROPROTEIN; VIMENTIN;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; COLLAGEN DEGRADATION; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FIBROSING ALVEOLITIS; FORCED VITAL CAPACITY; HUMAN; LONGITUDINAL STUDY; LUNG DIFFUSION CAPACITY; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; OBSERVATIONAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RISK ASSESSMENT; BLOOD; CLINICAL TRIAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FOLLOW UP;

AGED; BIOMARKERS; COHORT STUDIES; COLLAGEN; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; LONGITUDINAL STUDIES; MALE; MATRIX METALLOPROTEINASES; PROSPECTIVE STUDIES;

EID: 84930865108     PISSN: 22132600     EISSN: 22132619     Source Type: Journal    
DOI: 10.1016/S2213-2600(15)00048-X     Document Type: Article

References (33)

1. Navaratnam V, Fleming KM, West J, et al. The rising incidence of idiopathic pulmonary fibrosis in the UK. Thorax 2011, 66:462-467.
2. Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 2014, 370:2071-2082.
3. King TE, Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 2014, 370:2083-2092.
4. Maher TM PROFILEing idiopathic pulmonary fibrosis: rethinking biomarker discovery. Eur Respir Rev 2013, 22:148-152.
5. Li Y, Jiang D, Liang J, et al. Severe lung fibrosis requires an invasive fibroblast phenotype regulated by hyaluronan and CD44. J Exp Med 2011, 208:1459-1471.
6. McKleroy W, Lee TH, Atabai K Always cleave up your mess: targeting collagen degradation to treat tissue fibrosis. Am J Physiol Lung Cell Mol Physiol 2013, 304:L709-L721.
7. Pardo A, Selman M, Kaminski N Approaching the degradome in idiopathic pulmonary fibrosis. Int J Biochem Cell Biol 2008, 40:1141-1155.
8. Richards TJ, Kaminski N, Baribaud F, et al. Peripheral blood proteins predict mortality in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2012, 185:67-76.
9. DePianto DJ, Chandriani S, Abbas AR, et al. Heterogeneous gene expression signatures correspond to distinct lung pathologies and biomarkers of disease severity in idiopathic pulmonary fibrosis. Thorax 2015, 70:48-56.
10. Karsdal MA, Krarup H, Sand JM, et al. Review article: the efficacy of biomarkers in chronic fibroproliferative diseases-early diagnosis and prognosis, with liver fibrosis as an exemplar. Aliment Pharmacol Ther 2014, 40:233-249.
11. Skjot-Arkil H, Schett G, Zhang C, et al. Investigation of two novel biochemical markers of inflammation, matrix metalloproteinase and cathepsin generated fragments of C-reactive protein, in patients with ankylosing spondylitis. Clin Exp Rheumatol 2012, 30:371-379.
12. Leeming DJ, Sand JM, Nielsen MJ, et al. Serological investigation of the collagen degradation profile of patients with chronic obstructive pulmonary disease or idiopathic pulmonary fibrosis. Biomarker Insights 2012, 7:119-126.
13. Sand JM, Larsen L, Hogaboam C, et al. MMP mediated degradation of type IV collagen alpha 1 and alpha 3 chains reflects basement membrane remodeling in experimental and clinical fibrosis-validation of two novel biomarker assays. PLoS One 2013, 8:e84934.
14. Skjot-Arkil H, Clausen RE, Rasmussen LM, et al. Acute myocardial infarction and pulmonary diseases result in two different degradation profiles of elastin as quantified by two novel ELISAs. PLoS One 2013, 8:e60936.
15. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011, 183:788-824.
16. Cotes JE, Chinn DJ, Quanjer PH, Roca J, Yernault JC Standardization of the measurement of transfer factor (diffusing capacity). Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J Suppl 1993, 16:41-52.
17. Wells AU, Desai SR, Rubens MB, et al. Idiopathic pulmonary fibrosis: a composite physiologic index derived from disease extent observed by computed tomography. Am J Respir Crit Care Med 2003, 167:962-969.
18. Ley B, Ryerson CJ, Vittinghoff E, et al. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med 2012, 156:684-691.
19. Richeldi L, Ryerson CJ, Lee JS, et al. Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis. Thorax 2012, 67:407-411.
20. du Bois RM, Weycker D, Albera C, et al. Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference. Am J Respir Crit Care Med 2011, 184:1382-1389.
21. du Bois RM, Weycker D, Albera C, et al. Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011, 184:459-466.
22. Jensen RL, Teeter JG, England RD, White HJ, Pickering EH, Crapo RO Instrument accuracy and reproducibility in measurements of pulmonary function. Chest 2007, 132:388-395.
23. Raghu G, Collard HR, Anstrom KJ, et al. Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials. Am J Respir Crit Care Med 2012, 185:1044-1048.
24. Selman M, Ruiz V, Cabrera S, et al. TIMP-1, -2, -3, and -4 in idiopathic pulmonary fibrosis. A prevailing nondegradative lung microenvironment?. Am J Physiol Lung Cell Mol Physiol 2000, 279:562-574.
25. Selman M, Carrillo G, Estrada A, et al. Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern. PLoS One 2007, 2:e482.
26. Yamashita CM, Dolgonos L, Zemans RL, et al. Matrix metalloproteinase 3 is a mediator of pulmonary fibrosis. Am J Pathol 2011, 179:1733-1745.
27. Prasse A, Probst C, Bargagli E, et al. Serum CC-chemokine ligand 18 concentration predicts outcome in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2009, 179:717-723.
28. Yokoyama A, Kondo K, Nakajima M, et al. Prognostic value of circulating KL-6 in idiopathic pulmonary fibrosis. Respirology 2006, 11:164-168.
29. Greene KE, King TE, Kuroki Y, et al. Serum surfactant proteins-A and -D as biomarkers in idiopathic pulmonary fibrosis. Eur Respir J 2002, 19:439-446.
30. Leeming DJ, Karsdal MA, Byrjalsen I, et al. Novel serological neo-epitope markers of extracellular matrix proteins for the detection of portal hypertension. Aliment Pharmacol Ther 2013, 38:1086-1096.
31. Karsdal MA, Woodworth T, Henriksen K, et al. Biochemical markers of ongoing joint damage in rheumatoid arthritis-current and future applications, limitations and opportunities. Arthritis Res Ther 2011, 13:215.
32. Martinez FJ, de Andrade JA, Anstrom KJ, King TE, Raghu G Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis. N Eng J Med 2014, 370:2093-2101.
33. Wuyts WA, Antoniou KM, Borensztajn K, et al. Combination therapy: the future of management for idiopathic pulmonary fibrosis?. Lancet Respir Med 2014, 2:933-942.